Makes mass cytometry instruments for biomedical researchers.
Jun 2026Revenue $84.6M/yrExpenses $180M/yr
No trendCash runway ≈ 5.8 years from Jun 2026
Figures by year
When will Standard Biotools be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $84.6M and expenses $180M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $85.3M | $196M | −$110M |
| Dec 2024 | $91.0M | $218M | −$127M |
| Dec 2023 | $106M | $183M | −$76.6M |
| Dec 2022 | $97.9M | $214M | −$116M |
| Dec 2021 | $131M | $198M | −$67.5M |
| Dec 2020 | $138M | $189M | −$51.0M |
| Dec 2019 | $117M | $169M | −$51.8M |
| Dec 2018 | $113M | $161M | −$48.2M |
| Dec 2017 | $102M | $160M | −$58.4M |
| Dec 2016 | $104M | $178M | −$73.2M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.